{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:12:02Z","timestamp":1773274322092,"version":"3.50.1"},"reference-count":115,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/mcg.0b013e31819f66e2","type":"journal-article","created":{"date-parts":[[2009,7,14]],"date-time":"2009-07-14T07:26:50Z","timestamp":1247556410000},"page":"661-671","source":"Crossref","is-referenced-by-count":23,"title":["Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients"],"prefix":"10.1097","volume":"43","author":[{"given":"Andrew","family":"Aronsohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Reau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210305","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1002\/hep.1840360712","article-title":"Prevention of spread of hepatitis C","volume":"36","author":"Alter","year":"2002","journal-title":"Hepatology"},{"key":"R2-11-20210305","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"R3-11-20210305","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","volume":"9","author":"Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"key":"R4-11-20210305","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"R5-11-20210305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/hep.510270102","article-title":"Hepatitis C viral infection in the immunosuppressed patient","volume":"27","author":"Collier","year":"1998","journal-title":"Hepatology"},{"key":"R6-11-20210305","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/314720","article-title":"Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection","volume":"179","author":"Lesens","year":"1999","journal-title":"J Infect Dis"},{"key":"R7-11-20210305","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.1840140111","article-title":"The significance of antibody to hepatitis C virus in patients with chronic hepatitis B","volume":"14","author":"Fong","year":"1991","journal-title":"Hepatology"},{"key":"R8-11-20210305","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","author":"Adinolfi","year":"2001","journal-title":"Hepatology"},{"key":"R9-11-20210305","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.510270404","article-title":"Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis","volume":"27","author":"Corrao","year":"1998","journal-title":"Hepatology"},{"key":"R10-11-20210305","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cld.2007.04.008","article-title":"Current indications and contraindications for liver transplantation","volume":"11","author":"Ahmed","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R11-11-20210305","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"R12-11-20210305","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.1002\/hep.510260715","article-title":"Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials","volume":"26","author":"Carithers","year":"1997","journal-title":"Hepatology"},{"key":"R13-11-20210305","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular mechanisms of action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Rev Infect Dis"},{"key":"R14-11-20210305","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group","volume":"351","author":"Reichard","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"R15-11-20210305","first-page":"23","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R16-11-20210305","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R17-11-20210305","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R18-11-20210305","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200868060-00005","article-title":"Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b","volume":"68","author":"Scotto","year":"2008","journal-title":"Drugs"},{"key":"R19-11-20210305","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"R20-11-20210305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"R21-11-20210305","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2036.2002.01265.x","article-title":"Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C","volume":"16","author":"Kraus","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-11-20210305","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/hep.20482","article-title":"Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy","volume":"40","author":"Pockros","year":"2004","journal-title":"Hepatology"},{"key":"R23-11-20210305","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1053\/j.gastro.2004.01.027","article-title":"Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study","volume":"126","author":"Afdhal","year":"2004","journal-title":"Gastroenterology"},{"key":"R25-11-20210305","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/S0002-9343(99)00376-9","article-title":"Hepatitis C virus genotypes and quasispecies","volume":"107","author":"Davis","year":"1999","journal-title":"Am J Med"},{"key":"R26-11-20210305","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R27-11-20210305","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2036.2004.02208.x","article-title":"Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4","volume":"20","author":"Khuroo","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-11-20210305","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2008.06.003","article-title":"Hepatitis C virus and kidney disease","volume":"49","author":"Martin","year":"2008","journal-title":"J Hepatol"},{"key":"R29-11-20210305","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J Viral Hepat"},{"key":"R30-11-20210305","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"R31-11-20210305","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ndt\/gfg209","article-title":"Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency","volume":"18","author":"Bruchfeld","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R32-11-20210305","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00007691-200212000-00004","article-title":"Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis","volume":"24","author":"Bruchfeld","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R33-11-20210305","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2893.2005.00680.x","article-title":"Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients","volume":"13","author":"Bruchfeld","year":"2006","journal-title":"J Viral Hepat"},{"key":"R35-11-20210305","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2036.2004.02290.x","article-title":"Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis","volume":"20","author":"Fabrizi","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-11-20210305","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.1995.198","article-title":"Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients","volume":"47","author":"Pol","year":"1995","journal-title":"Kidney Int"},{"key":"R37-11-20210305","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.humpath.2003.08.012","article-title":"Reversibility of hepatitis C virus-related cirrhosis","volume":"35","author":"Pol","year":"2004","journal-title":"Hum Pathol"},{"key":"R38-11-20210305","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1053\/j.gastro.2004.09.013","article-title":"Hepatocellular carcinoma: recent trends in the United States","volume":"127","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"key":"R39-11-20210305","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"R40-11-20210305","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"R41-11-20210305","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1572-0241.2007.01092.x","article-title":"Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3","volume":"102","author":"Shiffman","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R43-11-20210305","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C","volume":"48","author":"Romero-Gomez","year":"2008","journal-title":"J Hepatol"},{"key":"R44-11-20210305","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R45-11-20210305","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R46-11-20210305","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R47-11-20210305","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R48-11-20210305","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-based therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"R49-11-20210305","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2893.2006.00749.x","article-title":"Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons","volume":"13","author":"Alvarez","year":"2006","journal-title":"J Viral Hepat"},{"key":"R52-11-20210305","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":"Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40\u2009kD)\/ribavirin therapy","volume":"43","author":"Jensen","year":"2006","journal-title":"Hepatology"},{"key":"R53-11-20210305","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1440-1746.2007.04904.x","article-title":"Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin","volume":"22","author":"Yu","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R54-11-20210305","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40\u2009kD)\/ribavirin","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"R55-11-20210305","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2005.10.003","article-title":"Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia","volume":"44","author":"Zeuzem","year":"2006","journal-title":"J Hepatol"},{"key":"R56-11-20210305","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferon-alpha-2a (40\u2009kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C","volume":"129","author":"von Wagner","year":"2005","journal-title":"Gastroenterology"},{"key":"R57-11-20210305","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"Yu","year":"2007","journal-title":"Gut"},{"key":"R58-11-20210305","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"R59-11-20210305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"R60-11-20210305","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"R62-11-20210305","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10620-006-9457-x","article-title":"Pegylated interferon and ribavirin failures: is retreatment an option?","volume":"52","author":"Cheruvattath","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R63-11-20210305","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2005.10.021","article-title":"Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study","volume":"44","author":"Cornberg","year":"2006","journal-title":"J Hepatol"},{"key":"R64-11-20210305","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1572-0241.2005.00282.x","article-title":"A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C","volume":"100","author":"Jacobson","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R65-11-20210305","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"Maylin","year":"2008","journal-title":"Gastroenterology"},{"key":"R68-11-20210305","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gut.2003.038257","article-title":"Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy","volume":"53","author":"Veldt","year":"2004","journal-title":"Gut"},{"key":"R69-11-20210305","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0168-8278(99)80129-9","article-title":"Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon","volume":"30","author":"Reichard","year":"1999","journal-title":"J Hepatol"},{"key":"R70-11-20210305","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","article-title":"Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy","volume":"127","author":"Marcellin","year":"1997","journal-title":"Ann Intern Med"},{"key":"R71-11-20210305","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1365-2893.2006.00829.x","article-title":"Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications","volume":"14","author":"Pradat","year":"2007","journal-title":"J Viral Hepat"},{"key":"R72-11-20210305","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/jmv.21257","article-title":"Immune suppression leading to hepatitis C virus re-emergence after sustained virological response","volume":"80","author":"Lin","year":"2008","journal-title":"J Med Virol"},{"key":"R73-11-20210305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MAJ.0b013e318159d1a8","article-title":"Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment","volume":"336","author":"Thomopoulos","year":"2008","journal-title":"Am J Med Sci"},{"key":"R74-11-20210305","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","article-title":"A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter study group","volume":"332","author":"Poynard","year":"1995","journal-title":"N Engl J Med"},{"key":"R75-11-20210305","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"R76-11-20210305","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.20073","article-title":"Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data","volume":"39","author":"Camma","year":"2004","journal-title":"Hepatology"},{"key":"R77-11-20210305","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"R78-11-20210305","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/135965350601100706","article-title":"Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV\/HIV-coinfected patients","volume":"11","author":"Barreiro","year":"2006","journal-title":"Antivir Ther"},{"key":"R79-11-20210305","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"R80-11-20210305","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.3748\/wjg.v13.i42.5648","article-title":"Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin","volume":"13","author":"Braks","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R83-11-20210305","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R84-11-20210305","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy","volume":"131","author":"Yoshida","year":"1999","journal-title":"Ann Intern Med"},{"key":"R85-11-20210305","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.510270529","article-title":"Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group","volume":"27","author":"Kasahara","year":"1998","journal-title":"Hepatology"},{"key":"R86-11-20210305","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-129-2-199807150-00005","article-title":"Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka hepatocellular Carcinoma prevention study group","volume":"129","author":"Imai","year":"1998","journal-title":"Ann Intern Med"},{"key":"R87-11-20210305","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(00)03595-9","article-title":"Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis","volume":"357","author":"Nishiguchi","year":"2001","journal-title":"Lancet"},{"key":"R89-11-20210305","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2169\/internalmedicine.47.1087","article-title":"Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients","volume":"47","author":"Hirakawa","year":"2008","journal-title":"Intern Med"},{"key":"R90-11-20210305","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.3748\/wjg.v13.i39.5180","article-title":"Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C","volume":"13","author":"Tanaka","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R91-11-20210305","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"R92-11-20210305","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"R93-11-20210305","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00007890-200201150-00010","article-title":"Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft","volume":"73","author":"Sanchez-Fueyo","year":"2002","journal-title":"Transplantation"},{"key":"R94-11-20210305","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/lt.21117","article-title":"A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation","volume":"13","author":"Yilmaz","year":"2007","journal-title":"Liver Transpl"},{"key":"R95-11-20210305","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/jlts.2002.31748","article-title":"A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation","volume":"8","author":"Crippin","year":"2002","journal-title":"Liver Transpl"},{"key":"R96-11-20210305","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-8278(03)00310-6","article-title":"Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation","volume":"39","author":"Forns","year":"2003","journal-title":"J Hepatol"},{"key":"R97-11-20210305","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy","volume":"42","author":"Everson","year":"2005","journal-title":"Hepatology"},{"key":"R98-11-20210305","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.510280334","article-title":"The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation","volume":"28","author":"Sheiner","year":"1998","journal-title":"Hepatology"},{"key":"R99-11-20210305","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.20560","article-title":"Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"R100-11-20210305","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0041-1345(00)02508-2","article-title":"Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment","volume":"33","author":"Mazzaferro","year":"2001","journal-title":"Transplant Proc"},{"key":"R101-11-20210305","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/lt.20157","article-title":"Outcomes of acute rejection after interferon therapy in liver transplant recipients","volume":"10","author":"Saab","year":"2004","journal-title":"Liver Transpl"},{"key":"R102-11-20210305","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"R103-11-20210305","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jhep.2006.12.017","article-title":"A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C","volume":"46","author":"Angelico","year":"2007","journal-title":"J Hepatol"},{"key":"R104-11-20210305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2036.2004.01919.x","article-title":"Hepatitis C virus-related extra-hepatic disease\u2014aetiopathogenesis and management","volume":"20","author":"Medina","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R105-11-20210305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005792-200001000-00005","article-title":"Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en medecine interne et maladies infectieuses sur le virus de l'Hepatite C","volume":"79","author":"Cacoub","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"R106-11-20210305","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/hep.1840190407","article-title":"Immunological disorders in C virus chronic active hepatitis: a prospective case-control study","volume":"19","author":"Pawlotsky","year":"1994","journal-title":"Hepatology"},{"key":"R107-11-20210305","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1046\/j.1365-2036.1999.00581.x","article-title":"Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia","volume":"13","author":"Calleja","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R108-11-20210305","first-page":"2172","article-title":"Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha","volume":"27","author":"Zuckerman","year":"2000","journal-title":"J Rheumatol"},{"key":"R109-11-20210305","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1023\/A:1026691416498","article-title":"Fatal exacerbation of hepatitis C-related cryoglobulinemia with interferon-alpha therapy","volume":"44","author":"Friedman","year":"1999","journal-title":"Dig Dis Sci"},{"key":"R110-11-20210305","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1007\/s10620-005-3059-x","article-title":"Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study","volume":"50","author":"D'Amico","year":"2005","journal-title":"Dig Dis Sci"},{"key":"R111-11-20210305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3810\/pgm.2003.02.1376","article-title":"Renal manifestations of hepatitis C virus infection. Extrahepatic complications often are silent\u2014and thus overlooked","volume":"113","author":"Bandi","year":"2003","journal-title":"Postgrad Med"},{"key":"R112-11-20210305","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0272-6386(12)70152-X","article-title":"Membranous glomerulonephritis in association with hepatitis C virus infection","volume":"22","author":"Davda","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"R113-11-20210305","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1046\/j.1523-1755.2003.00022.x","article-title":"Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy","volume":"63","author":"Rossi","year":"2003","journal-title":"Kidney Int"},{"key":"R114-11-20210305","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0002-9343(02)01257-3","article-title":"Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection","volume":"113","author":"Loustaud-Ratti","year":"2002","journal-title":"Am J Med"},{"key":"R115-11-20210305","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/ndt\/14.6.1558","article-title":"Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin","volume":"14","author":"Misiani","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"R116-11-20210305","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0168-8278(03)00346-5","article-title":"Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis","volume":"39","author":"Gisbert","year":"2003","journal-title":"J Hepatol"},{"key":"R117-11-20210305","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0168-8278(95)80438-2","article-title":"Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda","volume":"22","author":"Takikawa","year":"1995","journal-title":"J Hepatol"},{"key":"R118-11-20210305","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1023\/A:1018854906444","article-title":"Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C","volume":"43","author":"Sheikh","year":"1998","journal-title":"Dig Dis Sci"},{"key":"R119-11-20210305","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.2337\/dc06-0456","article-title":"Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection","volume":"29","author":"Simo","year":"2006","journal-title":"Diabetes Care"},{"key":"R120-11-20210305","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0168-8278(02)00067-3","article-title":"Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C","volume":"36","author":"Cacoub","year":"2002","journal-title":"J Hepatol"},{"key":"R121-11-20210305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1008884805251","article-title":"A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C","volume":"7","author":"Bayliss","year":"1998","journal-title":"Qual Life Res"},{"key":"R122-11-20210305","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.21565","article-title":"The effects of HCV infection and management on health-related quality of life","volume":"45","author":"Younossi","year":"2007","journal-title":"Hepatology"},{"key":"R123-11-20210305","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2006.10.009","article-title":"Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis","volume":"46","author":"Bonkovsky","year":"2007","journal-title":"J Hepatol"},{"key":"R124-11-20210305","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"R125-11-20210305","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gtc.2004.04.005","article-title":"Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond","volume":"33","author":"Fontana","year":"2004","journal-title":"Gastroenterol Clin North Am"},{"key":"R126-11-20210305","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004836-200908000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T23:48:46Z","timestamp":1739231326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-200908000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e31819f66e2","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}